



WP 5

Anke-Hilse Maitland-van der Zee

Farmaco-epidemiologie & Klinische Farmacologie



Universiteit Utrecht



Until now

- Validated proxy for ADRs to ACEI

[Change in prescription pattern as a potential marker for adverse drug reactions of angiotensin converting enzyme inhibitors.](#)

Mahmoudpour SH, Asselbergs FW, de Keyser CE, Souverein PC, Hofman A, Stricker BH, de Boer A, **Maitland-van der Zee** AH.

Int J Clin Pharm. 2015 Jul 10. [Epub ahead of print]

- Performed observational studies of ACEI use in CPRD

[Continuation of angiotensin converting enzyme inhibitor therapy, in spite of occurrence of angioedema.](#)

Mahmoudpour SH, Asselbergs FW, Terreehorst I, Souverein PC, de Boer A, **Maitland-van der Zee** AH.

Int J Cardiol. 2015 Aug 25;201:644-645. doi: 10.1016/j.ijcard.2015.08.185.

Hamid will show some more results

- Performed replication study of statin discontinuation GWAS in R'dam study
- Performed replication study of ACEI switch GWAS in R'dam study



Future plans

- REPLICATION of results from NGS
 - Rotterdam Study
 - Utrecht Cardiovascular Pharmacogenetics study
 - GENIUS-CHD
 - Study Bruce Psaty
 - EMERGE network
 - EUROPA trial (ACEI induced cough)
 - Extra cases and controles (please do not stop gathering cases!)
 - Other?

